Tenax Therapeutics
TENX
Tenax Therapeutics (TENX) news
Recent news
Tenax Therapeutics Inc: William Blair cuts to market perform rating
AInvest Wire · Aug 11, 2026Tenax Therapeutics shares plunge 87.2% after co's heart drug did not meet main goal in late-stage study
AInvest Wire · Aug 10, 2026Tenax Therapeutics exec says two deaths occurred during double-blind phase, with investigators determining both were unrelated to TNX-103 - conf call
Tenax Therapeutics, Inc. (Nasdaq: TENX) reported during a recent conference call that two deaths occurred during the double-blind phase of its ongoing Phase 3 LEVEL study of TNX-103 (oral levosimendan) for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction…
AInvest Wire · Aug 10, 2026Tenax Therapeutics shares sink 84% after trial misses endpoint
AInvest Wire · Aug 10, 2026Orion - license partner Tenax Therapeutics' Phase 3 level trial did not reach its primary endpoint
AInvest Wire · Aug 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.